FOLFOX, Nivolumab, Trastuzumab Fares Best in ERBB2-Positive Gastric Cancer
A chemotherapy-containing regimen appears more effective than a chemotherapy-free regimen as first-line therapy for ERBB2-positive gastric cancer.
A chemotherapy-containing regimen appears more effective than a chemotherapy-free regimen as first-line therapy for ERBB2-positive gastric cancer.
A team of researchers investigated the long-term effects of eliminating H pylori infection in patients at high risk for gastric cancer.
Researchers identified associations between pathogenic variants in BRCA1/2 and 7 cancers.
Patients with lymph node ratios of 9% or higher had better overall survival when they received adjuvant chemotherapy.
New research suggests aspirin may lower the risk for gastric adenocarcinoma in women but not in men.
The median overall survival was 17.45 months in the nivolumab arm and 17.15 months in the placebo arm.
The updated results are from a median survival follow-up of 18.5 months and 133 overall survival events.
About 59% of patients achieved a pathologic complete response.
Host-related biomarkers might predict toxicities associated with nivolumab treatment in patients with advanced gastric cancer
The addition of pembrolizumab to chemotherapy did not improve progression-free or overall survival.